Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aclarion, Inc. (ACON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8000-0.0263 (-3.18%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close0.8263
Open0.8500
Bid0.7900 x 1000
Ask0.8600 x 1300
Day's Range0.7920 - 0.8500
52 Week Range0.7700 - 4.0500
Volume48,962
Avg. Volume491,371
Market Cap6.257M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.1200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACON

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aclarion, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    24 days agoArgus Research
View more
  • ACCESSWIRE

    John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

    Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that John Keller M.D., Chief of Neurosurgery at University of Michigan Health-West and Neurosurgeon at Great Lakes Neurosurgical Associates in Grand Rapids, MI, will advise the company

  • ACCESSWIRE

    Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

    Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their participation in the Biomarkers for Evaluating Spine Treatments (BEST) Trial funded through the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM.

  • Newsfile

    Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

    Broomfield, Colorado--(Newsfile Corp. - August 4, 2022) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that Jeff Thramann, Executive Chairman, and Brent Ness, CEO, will be attending and presenting at the Q3 Virtual Investor Summit. During the presentation, the Company will provide an overview of its business an

Advertisement
Advertisement